COMMENTARY

Perhaps the title should have been “markets higher, but where are our charts?” The lack of leadership continues as we search for viable patterns. A bit of good news was the NAHB housing index or homebuilder confidence index was much better than expectations. The worse...

Just when this market looks week it reversed today on strong volume. Economic data was again less than desirable with the exception of jobless claims. Inflation is non-existent and Empire Manufacturing was once again weak and weaker than expected. Bank earnings were...

Economic data continues to disappoint as retail sales slumped. The slump could solely be blamed on falling gasoline prices. Bank earnings were mixed with BAC beating expectations while JPM missed. Volume jumped on both exchanges as JPM and WMT provided a lot of...

The market's win streak comes to an end as volume ticks higher. Today's session was a distribution day, but it was not all that bad. For now, only the NASDAQ and Russell 2000 have been rejected at their respective 50 day moving averages. S&P 500 still remains...

A light day on the street as Columbus Day had many off the job and enjoying a long weekend. Volume was off about 20% across the board. Light volume on Monday’s is no real surprise as many Monday’s have been light. The VIX has come back to earth in a hurry and is...

Biotech continues its woes as small caps lead the way once again. Utilities and Transportation stocks enjoyed stellar days too. VIX dropped further as investors expect future volatility to drop. Although today’s reversal was strong and it was a day where the Fed...

The Dow climbed higher due to DD as the company is going to split in two. Biotech once again was hit hard as sellers continue to pound the group. At one point today at the lows the NASDAQ was down more than 1% on the session. By the close, the NASDAQ was able to climb...

After a dismal jobs report Friday the market was able to confirm a new uptrend and we continued the gains today. Volume did not jump like it did on Friday, but was decent for a Monday. Biotech stocks continued to get hammered as fears over drug prices and the upcoming...